| Levomilnacipran | Allergan | ||
| 20,40,80,120 mg; Capsule, Extended Release |
Less Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| Indicated for the treatment of major depressive disorder (MDD) | |||
|
Yes
| |||
| Fetzima | Patent 1 | Patent 2 | Patent 3 |
|---|---|---|---|
| *** **** | ******* | ********* | ******* |
| ******** ****** | ******* | ******* | ******* |
| ******** ****** | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** **** | *** \ *** | ***** **, **** | ******* | ********* ******** | ******* *** **** *** *** **** |
| ******** ****** | *** \ ********* | *** *, **** | ******* | ******** | ******* *** **** *** *** **** |
| ******** ****** | *** \ ** | *** *, **** | ******* | ******** ************ | ***** ***-**** *********** |
Download ParaIV Report